StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3037% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Lipocine cash

Cash and short-term investments held at the end of each period.

Lipocine's cash was $23.27M at Jun 30, 2026. For fiscal 2025 it was $14.90M, down 31.1% from the year before. Over ten years it grew -2.9% a year on average. The highest annual figure on record is $45.26M in fiscal 2013.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.90M-31.1%
FY2024Dec 31, 2024$21.63M-1.8%
FY2023Dec 31, 2023$22.04M-32.3%
FY2022Dec 31, 2022$32.53M-27.1%
FY2021Dec 31, 2021$44.62M+126.9%
FY2020Dec 31, 2020$19.67M+3.1%
FY2019Dec 31, 2019$19.07M-5.8%
FY2018Dec 31, 2018$20.25M+54.9%
FY2017Dec 31, 2017$13.08M+135.2%
FY2016Dec 31, 2016$5.56M-72.2%
FY2015Dec 31, 2015$20.01M-27.7%
FY2014Dec 31, 2014$27.67M-38.9%
FY2013Dec 31, 2013$45.26M+741.8%
FY2012Dec 31, 2012$5.38M-37.2%
FY2011Dec 31, 2011$8.57M–
FY2010Dec 31, 2010$0–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$23.27M+29.7%
Q1 FY2026Mar 31, 2026$24.73M+25.4%
Q4 FY2025Dec 31, 2025$14.90M-31.1%
Q3 FY2025Sep 30, 2025$15.13M-23.7%
Q2 FY2025Jun 30, 2025$17.94M-20.5%
Q1 FY2025Mar 31, 2025$19.72M-19.9%
Q4 FY2024Dec 31, 2024$21.63M-1.8%
Q3 FY2024Sep 30, 2024$19.82M-16.9%
Q2 FY2024Jun 30, 2024$22.55M-12.6%
Q1 FY2024Mar 31, 2024$24.63M-14.7%
Q4 FY2023Dec 31, 2023$22.04M-32.3%
Q3 FY2023Sep 30, 2023$23.85M-30.4%
Q2 FY2023Jun 30, 2023$25.79M-31.0%
Q1 FY2023Mar 31, 2023$28.87M-31.3%
Q4 FY2022Dec 31, 2022$32.53M-27.1%
Q3 FY2022Sep 30, 2022$34.26M-11.4%
Q2 FY2022Jun 30, 2022$37.40M-19.8%
Q1 FY2022Mar 31, 2022$42.00M-7.4%
Q4 FY2021Dec 31, 2021$44.62M+126.9%
Q3 FY2021Sep 30, 2021$38.66M+105.7%
Q2 FY2021Jun 30, 2021$46.64M+154.8%
Q1 FY2021Mar 31, 2021$45.35M+120.3%
Q4 FY2020Dec 31, 2020$19.67M+3.1%
Q3 FY2020Sep 30, 2020$18.80M+13.6%
Q2 FY2020Jun 30, 2020$18.30M+111.3%
Q1 FY2020Mar 31, 2020$20.58M+150.3%
Q4 FY2019Dec 31, 2019$19.07M-5.8%
Q3 FY2019Sep 30, 2019$16.55M–
Q2 FY2019Jun 30, 2019$8.66M+31.2%
Q1 FY2019Mar 31, 2019$8.22M-4.0%
Q4 FY2018Dec 31, 2018$20.25M+54.9%
Q3 FY2018Sep 30, 2018$0-100.0%
Q2 FY2018Jun 30, 2018$6.60M-60.3%
Q1 FY2018Mar 31, 2018$8.56M+23.4%
Q4 FY2017Dec 31, 2017$13.08M+135.2%
Q3 FY2017Sep 30, 2017$9.27M+97.0%
Q2 FY2017Jun 30, 2017$16.63M–
Q1 FY2017Mar 31, 2017$6.94M–
Q4 FY2016Dec 31, 2016$5.56M–
Q3 FY2016Sep 30, 2016$4.71M–

More Lipocine figures

See a number that looks wrong?